Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes

Journal of Diabetes Investigation

Volumn 7, Issue 5, 2016, Pages 769-776

  Huang, Chung Huei ^a   Huang, Yu Yao ^a   Hsu, Brend Ray Sea ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Glycemic control; Statin; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DYSLIPIDEMIA; ELECTRONIC MEDICAL RECORD; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

EID: 84991079016     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12483     Document Type: Article

References (33)

1. Maruyama T, Takada M, Nishibori Y, et al. Comparison of preventive effect on cardiovascular events with different statins. Circ J 2011; 75: 1951–1959.
2. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 449–508.
3. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin. J Am Coll Cardiol 2011; 57: 1535–1545.
4. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013; 346: f2610.
5. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 2011; 305: 2556–2564.
6. Sattar N, Preiss D, Murray HM, et al. Statin and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735–742.
7. Chen JCN. Risk-benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes. J Diabetes Investig 2013; 4: 344–346.
8. Yamazaki T, Kishimoto J, Ito C, et al. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int 2011; 2: 134–140.
9. Odawara M, Yamazaki T, Kishimoto J, et al. Pitavastatin for the delay or prevention of diabetes prevention in individuals with impaired glucose tolerance. In: 61-LB, 73th American Diabetes Association Annual Meeting 2013.
10. Choi SH, Lim S, Hong ES, et al. PROPIT: a PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome. Clin Endocrinol 2015; 82: 670–677.
11. Daido H, Horikawa Y, Takeda J. The effects of pitavastatin on glucose metabolism in patients with type 2 diabetes with hypercholesterolemia. Diabetes Res Clin Pract 2014; 106: 531–537.
12. Cho Y, Choe E, Lee YH, et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism 2014; 64: 482–488.
13. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006; 13: 123–129.
14. Son JW, Kim DJ, Lee CB, et al. Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes. J Diabetes Investig 2013; 4: 466–474.
15. Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008; 15: 269–275.
16. Takano T, Yamakawa T, Takahashi M, et al. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2006; 13: 95–100.
17. Sabatine MS, Wiviott SD, Morrow DA, et al. High dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 2004; 110(Supplement III): 834.
18. Yokote K, Saito Y; CHIBA study investigators. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb 2009; 16: 297–298.
19. Gumprecht J, Gosho M, Budinski D, et al. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab 2011; 13: 1047–1055.
20. Mita T, Nakayama S, Abe H, et al. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig 2013; 4: 297–303.
21. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients-collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008; 201: 345–352.
22. Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009; 4: 291–302.
23. Hiro T, Kimura T, Morimoto T, et al. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome – serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circ J 2010; 74: 1165–1174.
24. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison on the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein and glucose intolerance. Clin Ther 2008; 30: 1089–1101.
25. Maejima T, Yamazaki H, Aoki T, et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004; 324: 835–839.
26. Saiki A, Murano T, Watanabe F, et al. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 2005; 12: 163–168.
27. Teramoto T, Shimano H, Yokoto K, et al. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb 2009; 16: 654–661.
28. Katayama T. Usefulness of pitavastatin on lipid profile and glucose metabolism in hypercholesterolemia with diabetes mellitus. Prog Med 2005; 25: 3110–3115 (Japanese).
29. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009; 119: 2103–2111.
30. Yamada A, Arita M, Furuta M, et al. The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. Diabetes Res Clin Pract 2008; 82: 127–131.
31. Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. Am J Med 2006; 119: 24S–30S.
32. Ishikawa M, Okajima F, Inoue N, et al. Distinct effects of pravastatin, atorvastatin, and Simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006; 13: 329–335.
33. Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881–1892.